About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sensus Healthcare, Inc. - Common Stock (NQ:SRTS)

3.940 +0.010 (+0.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,793
Open 4.070
Bid (Size) 3.880 (100)
Ask (Size) 4.550 (100)
Prev. Close 3.930
Today's Range 3.940 - 4.100
52wk Range 3.030 - 5.920
Shares Outstanding 16,462,059
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
From Sensus Healthcare, Inc.
Via Business Wire

Performance

YTD
-3.9%
-3.9%
1 Month
-6.6%
-6.6%
3 Month
-18.4%
-18.4%
6 Month
+18.0%
+18.0%
1 Year
-15.8%
-15.8%

More News

Read More
News headline image
Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
From Sensus Healthcare, Inc.
Via Business Wire
Sensus Healthcare Inc (NASDAQ:SRTS) Stock Plummets After Q4 Earnings and Revenue Miss ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Sensus Healthcare SRTS Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Healthcare Appoints Eric Sachetta to its Board of Directors
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus SRTS Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Sensus Healthcare Inc (NASDAQ:SRTS) Beats Q3 2025 Earnings Estimates Despite Revenue Decline ↗
Via Chartmill
News headline image
Sensus Healthcare Reports Third Quarter 2025 Financial Results
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Healthcare Named to TIME’s America’s Growth Leaders of 2026
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Healthcare Announces the Passing of Director Bill McCall
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
Sensus Healthcare to Report Third Quarter 2025 Financial Results and Hold Business Update Conference Call on November 6
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
SENSUS INVESTIGATION REMINDER: Bragar Eagel & Squire, Reminds Sensus Healthcare Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Sensus Stockholders
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Study Published in Dermatologic Therapy Shows Efficacy of Sensus Healthcare’s SRT Combined with Punch Excision to Treat Keloids
From Sensus Healthcare, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTS
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc. - SRTS
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Sensus Healthcare, Inc. - Common Stock publicly traded?
Yes, Sensus Healthcare, Inc. - Common Stock is publicly traded.
What exchange does Sensus Healthcare, Inc. - Common Stock trade on?
Sensus Healthcare, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sensus Healthcare, Inc. - Common Stock?
The ticker symbol for Sensus Healthcare, Inc. - Common Stock is SRTS on the Nasdaq Stock Market
What is the current price of Sensus Healthcare, Inc. - Common Stock?
The current price of Sensus Healthcare, Inc. - Common Stock is 3.940
When was Sensus Healthcare, Inc. - Common Stock last traded?
The last trade of Sensus Healthcare, Inc. - Common Stock was at 04/24/26 04:00 PM ET
What is the market capitalization of Sensus Healthcare, Inc. - Common Stock?
The market capitalization of Sensus Healthcare, Inc. - Common Stock is 64.86M
How many shares of Sensus Healthcare, Inc. - Common Stock are outstanding?
Sensus Healthcare, Inc. - Common Stock has 65M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.